Effect of LY450139 a y-Secretase Inhibitor, on the Progression of Alzheimer's Disease as Compared With Placebo.
Phase of Trial: Phase III
Latest Information Update: 28 Jul 2016
At a glance
- Drugs Semagacestat (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms IDENTITY-2
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 28 Apr 2012 Additional trial location added as reported by European Clinical Trials Database.
- 28 Apr 2012 Planned number of patients changed from 1100 to 1500 as reported by European Clinical Trials Database.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History